Second-line afatinib increases progression-free survival (PFS) in metastatic head and neck cancer

Second-line afatinib increases progression-free survival (PFS) in metastatic head and neck cancer

EMJ

5 years
1,263 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of a Phase III study looking at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer after failure of platinum-based chemotherapy.
Up Next Autoplay
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 5 minutes
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
1 Views
Cancer-News 55 minutes
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
0 Views
Cleveland Clinic 1 hour
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
1 Views
Cancer-News 1 hour
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Category: Immunotherapy
0 Views
Cleveland Clinic 1 hour
Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Category: Immunotherapy
1 Views
Cleveland Clinic 1 hour
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
Category: News
2 Views
alexvarney 2 hours
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 16 hours
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Category: News
3 Views
alexvarney 22 hours
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
2 Views
alexvarney 23 hours